Cardiac resynchronization therapy with defibrillation capability: Considerations on a not yet proven therapeutic superiority;Terapia di risincronizzazione cardiaca in combinazione con la funzione di cardioversione-defibrillazione: Considerazioni su una superiorità terapeutica ancora da dimostrare

Giornale Italiano di Cardiologia

Volumn 11, Issue 4, 2010, Pages 295-305

  Berisso, Massimo Zoni ^a   Canonero, Daniele ^a   Caruso, Davide ^a   Setti, Sergio ^a   Domenicucci, Stefano ^a  

^a Padre A Micone Hospital   (Italy)

Author keywords

Cardiac resynchronization therapy; Heart failure; Implantable cardioverter defibrillator; Sudden cardiac death

Indexed keywords

CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVERSION; DEFIBRILLATION; HEART FAILURE; HUMAN; MORTALITY; QUALITY OF LIFE; REVIEW; SURVIVAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; CARDIAC PACING, ARTIFICIAL; CLINICAL TRIALS AS TOPIC; COMORBIDITY; ELECTRIC COUNTERSHOCK; HEART FAILURE; HEART FUNCTION TESTS; HUMANS; META-ANALYSIS AS TOPIC; MULTICENTER STUDIES AS TOPIC; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77952297085     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1214-8. (Pubitemid 26117716)
2. Miller LW, Missov ED. Epidemiology of heart failure. Cardiol Clin 2001; 19: 547-555
3. Swedberg K, Cleland J, Drexler H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). The Task Force for the diagnosis and treatment of CHF of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140
4. American Heart Association. Heart disease and stroke statistics - 2003 update. Dallas, TX: American Heart Association, 2002.
5. Orn S, Dickstein K. How do heart failure patients die? Eur Heart J Suppl 2002; 4 (Suppl D): D59-D65.
6. Abraham WT. Cardiac resynchronization therapy for heart failure: biventricular pacing and beyond. Curr Opin Cardiol 2002; 17: 346-352 (Pubitemid 34864601)
7. St John Sutton MG, Plappert T, Abraham WT, et al, for the Multicenter InSync Randomized Clinical Evaluation (MIRA-CLE) Study Group. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003; 107: 1985-1990.
8. Abraham WT, Fisher WG, Smith AL, et al, for the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-1853.
9. Cazeau S, Leclercq C, Lavergne T, et al, for the Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873-880
10. Auricchio A, Stellbrink C, Sack S, et al, for the Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002; 39: 2026-2033
11. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the Multisite Stimulation in Cardiomyopathies (MUSTIC) study. J Am Coll Cardiol 2002; 40: 111-118 (Pubitemid 34701385)
12. Bristow MR, Saxon LA, Boehmer J, et al, for the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150 La terapia di risincronizzazione cardiaca associate alla funzione di cardioversione- defibrillazione riduce la mortalità totale e migliora la qualità della vita dei pazienti con scompenso cardiaco refrattario a terapia medica ottimale, grave disfunzione ventricolare sistolica e dissincronia cardiaca.
13. Cleland JG, Daubert JC, Erdmann E, et al, for the Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549
14. McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction. A systematic review. JAMA 2007; 297: 2502-2514 La terapia di risincronizzazione cardiaca associate alla funzione di cardioversione-defibrillazione non è superiore alla sola terapia di risincronizzazione cardiaca nell'allungare Ia sopravvivenza. (Pubitemid 46953404)
15. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, Boersma E, Simoons M, Jordaens LJ. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J 2006; 27: 2682-2688 (Pubitemid 44729869)
16. Ellenbogen KA, Wood MA, Klein HU. Why should we care about CARE-HF? J Am Coll Cardiol 2005; 46: 2199-2203
17. Daubert JC, Leclercq C, Mabo P. There is plenty of room for cardiac resynchronization therapy devices without back-up defibrillators in the electrical treatment of heart failure. J Am Coll Cardiol 2005; 46: 2204-2207 (Pubitemid 41785486)
18. Ermis C, Benditt DG. Cardiac resynchronization pacing without defibrillator capability: is this a viable option? Europace 2006; 8: 499-501.
19. Ypenburg C, van Erven L, Bleeker GB, et al. Benefit of combined resynchronization and defibrillator therapy in heart failure patients with and without ventricular arrhythmias. J Am Coll Cardiol 2006; 48: 464-470 (Pubitemid 44093957)
20. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442
21. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in the adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016.
22. Salukhe TV, Dimopoulos K, Sutton R, Coats AJ, Piepoli M, Francis DP. Life-years gained from defibrillator implantation: markedly nonlinear increase during 3 years of follow-up and its implications. Circulation 2004; 109: 1848-1853 (Pubitemid 38509118)
23. Bardy GH, Lee KL, Mark DB, et al, for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237
24. Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the Cardiac Resynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006; 27: 1928-1932 Rispetto alla terapia medica ottimale la terapia di risincronizzazione cardiaca riduce la mortalità totale per diminuzione dei decessi dovuti sia a scompenso cardiaco progressivo che a tachiaritmie ventricolari. (Pubitemid 44297365)
25. Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol 1997; 30: 1589-1597
26. Krahn AD, Connolly SJ, Roberts RS, Gent M, for the ATMA Investigators. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. Am Heart J 2004; 147: 837-840
27. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113: 1424-1433 (Pubitemid 43739439)
28. Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007; 116: 392-398 (Pubitemid 47196544)
29. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003; 42: 1226-1233 (Pubitemid 37188347)
30. Huynh BC, Royner A, Rich MW. Long-term survival in elderly patients hospitalized for heart failure: 14-year follow-up from a prospective randomized trial. Arch Intern Med 2006; 166: 1892-1898
31. Bouvy ML, Heerdink ER, Leufkens HG, Hoes AW. Predicting mortality in patients with heart failure: a pragmatic approach. Heart 2003; 89: 605-609 (Pubitemid 36606200)
32. Parkash R, Stevenson WG, Epstein LM, Maisel WH. Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection. Am Heart J 2006; 151: 397-403. (Pubitemid 43144742)
33. Yarnoz MJ, Curtis AB. Why cardioverter-defibrillator implantation might not be the best idea for your elderly patient. Am J Geriatr Cardiol 2006; 15: 367-371
34. Lee DS, Tu JV, Austin PC, et al. Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol 2007; 49: 2408-2415 L'età avanzata e la comorbilità non cardiaca sono fattori che diminuiscono di molto l'efficacia del cardioverter-defibrillatore impiantabile nel ridurre la mortalità totale.
35. Goldenberg I, Vyas AK, Hall JW, et al, for the MADIT II Investigators. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008; 51: 288-296
36. Daubert JP, Sesselberg HW, Huang DT. Implantable cardioverter- defibrillators for primary prevention: how do the data pertain to the aged? Am J Geriatr Cardiol 2006; 15: 88-92.
37. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 955-962 (Pubitemid 32912694)
38. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002; 8: 136-141 (Pubitemid 34857278)
39. Goldenberg I, Moss AJ, Brown M, et al, for the Executive Committee of the Multicenter Automatic Defibrillator Implantation Trial-II. Long-term outcome after implantation of a cardioverter-defibrillator: an eight year follow-up study of the Multicenter Automatic Defibrillator Trial II. Late breaking clinical Trials I. http://www.heartrhythmondemand.org/heartrhythm2009/SP117552/ play/?prd=090502-SP11-7552&prn=SP11.7552 [accessed December 10, 2009].
40. Goldberg LR, Jessup M. A time to be born and a time to die. Circulation 2007; 116: 360-362
41. Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007; 115: 204-12. (Pubitemid 46105719)
42. Auricchio A, Metra M, Gasparini M, et al, for the Multicenter Longitudinal Observational Study (MILOS) Group. Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. Am J Cardiol 2007; 99: 232-238 Nella pratica clinica quotidiana I'efficacia della terapia di risincronizzazione cardiaca associata alla funzione di cardioversione-defibrillazione risulta equivalente alla sola terapia di risincronizzazione cardiaca in termini di riduzione della mortalità totale.
43. Carson P, Anand I, O'Connor C, et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillator Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005; 46: 2329-2334 (Pubitemid 41785506)
44. Medina-Ravell VA, Lankipalli RS, Yan GX, et al. Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes? Circulation 2003; 107: 740-746
45. Guerra JM, Wu J, Miller JM, Groh WJ. Increase in ventricular tachycardia frequency after biventricular implantable cardioverter-defibrillator upgrade. J Cardiovasc Electrophysiol 2003; 14: 1245-1247 (Pubitemid 37455415)
46. Berger T, Hanser F, Hintringer F, et al. Effects of cardiac resynchronization therapy on ventricular repolarization in patients with congestive heart failure. J Cardiovasc Electrophysiol 2005; 16: 611-617 (Pubitemid 40807650)
47. Young JB, Abraham WT, Smith AL, et al, for the Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE-ICD Trial. JAMA 2003; 289: 2685-2694
48. Zagrodzky JD, Ramaswamy K, Page RL, et al. Biventricular pacing decreases the inducibility of ventricular tachycardia in patients with ischemic cardiomyopathy. Am J Cardiol 2001; 87: 1208-1210 (Pubitemid 32453247)
49. Higgins SL, Yong P, Sheck D, et al, for the Ventak CHF Investigators. Biventricular pacing diminishes the need for implantable cardioverter defibrillator therapy. J Am Coll Cardiol 2000; 36: 824-827
50. McSwain RL, Schwartz RA, DeLurgio DB, Mera FV, Langberg JJ, León AR. The impact of cardiac resynchronization therapy on ventricular tachycardia/fibrillation: an analysis from the combined Contak-CD and InSynk-ICD studies. J Cardiovasc Electrophysiol 2005; 16: 1168-1171 (Pubitemid 43920004)
51. Ermis C, Seutter R, ZhU AX, et al. Impact of upgrade to cardiac resynchronization therapy on ventricular arrhythmia frequency in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol 2005; 46: 2258-2263 (Pubitemid 41785494)
52. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997; 80: 26L-40L.
53. Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008; 117: 2608-2616
54. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004; 95: 754-763
55. Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000; 102: 611-616 (Pubitemid 30640659)
56. Buxton AE, Lee KL, Haf ley GE, et al, for the MUSTT Investigators. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation 2002; 106: 2466-2472
57. Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJ. Out-of-hospital cardiac arrest - the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 2003; 24: 1204-1209
58. Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 2006; 47: 1161-1166
59. Curtis JP, Sokol SI, Wang Y, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003; 42: 736-742 (Pubitemid 37000196)
60. de Sousa MR, Morillo CA, Rabelo FT, Nogueira Filho AM, Ribeiro AL. Non-sustained ventricular tachycardia as a predictor of sudden cardiac death in patients with left ventricular dysfunction: a meta-analysis. Eur J Heart Fail 2008; 10: 1007-1014
61. Daubert JP, Zareba W, Hall WJ, et al, for the MADIT II Study Investigators. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol 2006; 47: 98-107. (Pubitemid 43005171)
62. Grimm W, Hoffmann J, Menz V, Luck K, Maisch B. Programmed ventricular stimulation for arrhythmia risk prediction in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia. J Am Coll Cardiol 1998; 32: 739-745 (Pubitemid 28435263)
63. Turitto G, Ahuja RK, Caref EB, el-Sherif N. Risk stratification for arrhythmic events in patients with nonischemic dilated cardiomyopathy and nonsustained ventricular tachycardia: role of programmed ventricular stimulation and signal-averaged electrocardiogram. J Am Coll Cardiol 1994; 24: 1523-1528 (Pubitemid 24344249)
64. Kusmirek SL, Gold MR. Sudden cardiac death: the role of risk stratification. Am Heart J 2007; 153 (Suppl 4): 25-33. (Pubitemid 46466710)
65. Grimm W, Christ M, Bach J, Müller HH, Maisch B. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 2003; 108: 2883-2891 (Pubitemid 37517816)
66. Salerno-Uriarte JA, De Ferrari GM, Klersy C, et al, for the AL-PHA Study Group Investigators. Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study. J Am Coll Cardiol 2007; 50: 1896-1904
67. Myles RC, Jackson CE, Tsorlalis I, Petrie MC, McMurray JJ, Cobbe SM. Is microvolt T-wave alternans the answer to risk stratification in heart failure? Circulation 2007; 116: 2984-2991
68. Bloomfield DM, Bigger JT, Steinman RC, et al Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. J Am Coll Cardiol 2006; 47: 456-463 (Pubitemid 43063271)
69. Gehi AK, Stein RH, Metz LD, Gomes JA. Microvolt T-wave alternans for the risk stratification of ventricular tachyarrhythmic events: a meta-analysis. J Am Coll Cardiol 2005; 46: 75-82.
70. La Rovere MT, Pinna GD, Maestri R, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003; 107: 565-570 (Pubitemid 36176805)
71. Galinier M, Pathak A, Fourcade J, et al. Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. Eur Heart J 2000; 21: 475-482 (Pubitemid 30122135)
72. Bilchick KC, Fetics B, Djoukeng R, et al. Prognostic value of heart rate variability in chronic congestive heart failure (Veterans Affairs' Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure). Am J Cardiol 2002; 90: 24-28 (Pubitemid 34671197)
73. Guzzetti S, La Rovere MT, Pinna GD, et al. Different spectral components of 24 h heart rate variability are related to different modes of death in chronic heart failure. Eur Heart J 2005; 26: 357-362 (Pubitemid 40283094)
74. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998; 98: 1510-1516 (Pubitemid 28481667)
75. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392-2397 (Pubitemid 34556391)
76. Vrtovec B, Delgado R, Zewail A, Thomas CD, Richartz BM, Radovancevic B. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation 2003; 107: 1764-1769 (Pubitemid 36418357)
77. Verma A, Kilicaslan F, Martin DO, et al. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies. Heart 2006; 92: 190-195 (Pubitemid 43131958)
78. Zoni Berisso M, Cavallini A, lannetti M. Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption. Am J Cardiol 1984; 54: 677-679 (Pubitemid 14073272)
79. Bayés de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117: 151-159 (Pubitemid 19043766)
80. Paganelli F, Barnay P, Imbert-Joscht I, et al. Influence of residual myocardial ischaemia on induced ventricular arrhythmias following a first acute myocardial infarction. Eur Heart J 2001; 22: 1931-1937 (Pubitemid 33054673)
81. Elhendy A, Chapman S, Porter TR, Windle J. Association of myocardial ischemia with mortality and implantable cardioverter-defibrillator therapy in patients with coronary artery disease at risk of arrhythmic death. J Am Coll Cardiol 2005; 46: 1721-1726 (Pubitemid 41531629)
82. Singh JP, Hall WJ, McNitt S, et al, for the MADIT II Investigators. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II). J Am Coll Cardiol 2005; 46: 1712-1720 (Pubitemid 41531628)
83. Holmes DR Jr, Davis KB, Mock MB, et al. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: a report from the Coronary Artery Surgery Study. Circulation 1986; 73: 1254-1263
84. European Coronary Surgery Study Group. Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. Lancet 1982; 2: 1173-1180
85. Zoni Berisso M, Caruso D, Canonero D, Setti S, Domenicucci S. Uso profilattico del cardioverter-defibrillatore impiantabile nei pazienti con grave disfunzione ventricolare sinistra: come districarsi tra linee guida, pratica clinica, problemi etici e limitazione delle risorse. G Ital Cardiol 2008; 9: 338-354
86. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 8: 746-837. (Pubitemid 44362500)
87. Zoni Berisso M, Delfino L, Viani S. Nei pazienti con insufficienza cardiaca il cardioverter-defibrillatore impiantabile ritarda la morte o salva la vita? Ital Heart J Suppl 2002; 3: 36-44.
88. Moss AJ, Greenberg H, Case RB, et al, for the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004; 110: 3760-3765 (Pubitemid 38496355)
89. Saxon LA, Bristow MR, Boehmer J, et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circulation 2006; 114: 2766-2772
90. Feldman AM, de Lissovoy G, Bristow MR, et al. Cost-effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. J Am Coll Cardiol 2005; 46: 2311-2321
91. Gold MR, Peter RW, Johnson JW, Shorofsky SR. Complications associated with pectoral implantation of cardioverter defibrillators. World-wide Jewell Investigators. Pacing Clin Electro7 physiol 1997; 20 (1 Pt 2): 208-211
92. Maisel WH, Moynahan M, Zuckerman BD, et al. Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA 2006; 295: 1901-1906
93. Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007; 28: 42-51. (Pubitemid 46134956)
94. Hlatky MA. Cost-effectiveness of cardiac resynchronization therapy. J Am Coll Cardiol 2005; 46; 2322-2324
95. National Institute for Health and Clinical Excellence. Cardiac resynchronization therapy for the treatment of heart failure. Nice Technology Appraisal Guidance 120. http://www.nice.org.uk/nicemedia/pdf/TA120Guidance.pdf [accessed December 10, 2009].
96. Chen L, Hay JW. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther 2004; 18: 161-170 (Pubitemid 38987363)
97. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005; 353: 1471-1480
98. Sanders GD, Hlatky MA, Owens DK. Special report: cost-effectiveness of implantable cardioverter-defibrillators in a MA-DIT-II population. Chicago, IL: Blue Cross and Blue Shield Association. Technology Evaluation Center Assessment Program Report: 2004; 19 (3).
99. Weiss JP, Saynina O, McDonald KM, McClellan MB, Hlatky MA. Effectiveness and cost-effectiveness of implantable cardioverter-defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries. Am J Med 2002; 112: 519-527 (Pubitemid 34518310)
100. Hay J, La Bree L, Luo R, et al. Cost-effectiveness of preventive occupational therapy for independent living adults. J Am Geriatr Soc 2002; 50: 1381-1388
101. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16: 1-31.
102. Graham JD, Corso PS, Morris JM, Segui-Gomez M, Weinstein MC. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health 1998; 19: 125-182 (Pubitemid 28279927)
103. Neumann PJ, Rosen AB, Weinstein MC Medicare and cost-effectiveness analysis. N Engl J Med 2005; 353: 1516-1522
104. Linde C, Abraham WT, Gold MR, et al, for the REVERSE Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008; 52: 1834-1843
105. Moss AJ, Hall WJ, Cannom DS, et al, for the MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: 1329-1338